SCHEMBL11269191

SCHEMBL11269191

Fc1ccc(C2=NCCc3ccccc32)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK10 P53779 5/20 0.55
NOS3 P29474 2/20 0.49
NOS2 P35228 1/20 0.49
MAOA P21397 1/20 0.44
HTR1A P08908 1/20 0.41
HTR7 P34969 1/20 0.41
ALDH1A1 P00352 3/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
TP53 P04637 1/20 0.40
POLB P06746 1/20 0.40
PKM P14618 1/20 0.40
NFKB1 P19838 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
LMNA P02545 1/20 0.40
CA1 P00915 2/20 0.40
CA2 P00918 2/20 0.40
CA7 P43166 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29498359 1.00 MAPK10 (0.55) MAPK10NOS3NOS2MAOAHTR1A
SCHEMBL29498358 1.00 MAPK10 (0.55) MAPK10NOS3NOS2MAOAHTR1A
SCHEMBL163051 0.85 MAPK10 (0.55) MAPK10NOS3NOS2MAOAALDH1A1
SCHEMBL29384557 0.85 MAPK10 (0.55) MAPK10NOS3NOS2MAOAALDH1A1
SCHEMBL30965966 0.85 NOS3 (0.47) MAPK10NOS3NOS2MAOAHTR1A
Hydrochloric Acid SCHEMBL27495714 0.84 MAPK10 (0.54) MAPK10NOS3NOS2MAOAALDH1A1
SCHEMBL6718892 0.83 NOS3 (0.58) MAPK10NOS3NOS2MAOAALDH1A1
SCHEMBL13805616 0.83 NOS3 (0.49) MAPK10NOS3NOS2MAOAALDH1A1
SCHEMBL21063722 0.83 CA1 (0.52) MAPK10NOS3NOS2MAOAALDH1A1
SCHEMBL28542282 0.83 MAPK10 (0.50) MAPK10NOS3NOS2MAOAHTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113950477-B Granulin precursor modulators and methods of use thereof 阿库达医疗公司 2024-07-05 CN disclosed
CN-114195713-B Method for synthesizing dihydroisoquinoline by catalyzing selective dehydrogenation of tetrahydroisoquinoline 广东众源药业有限公司 2023-11-17 CN disclosed
EP-3724188-B1 PROGRANULIN MODULATORS AND METHODS OF USING THE SAME ARKUDA THERAPEUTICS (US) 2023-06-07 EP disclosed
EP-3724188-B1 PROGRANULIN MODULATORS AND METHODS OF USING THE SAME ARKUDA THERAPEUTICS (US) 2023-06-07 EP disclosed
US-20220409593-A1 PROGRANULIN MODULATORS AND METHODS OF USING THE SAME ARKUDA THERAPEUTICS 2022-12-29 US disclosed
US-20220409593-A1 PROGRANULIN MODULATORS AND METHODS OF USING THE SAME ARKUDA THERAPEUTICS 2022-12-29 US disclosed
EP-4048677-A1 PROGRANULIN MODULATORS AND METHODS OF USING THE SAME Arkuda Therapeutics (US) 2022-08-31 EP disclosed
US-20220251084-A1 PROGRANULIN MODULATORS AND METHODS OF USING THE SAME JANSSEN PHARMACEUTICA NV (BE) 2022-08-11 US disclosed
CN-112500345-B Synthetic method of alpha-cyano quaternary carbon substituted tetrahydroisoquinoline compound 西安石油大学 2022-06-21 CN disclosed
EP-3983401-A1 PROGRANULIN MODULATORS AND METHODS OF USING THE SAME Arkuda Therapeutics (US) 2022-04-20 EP disclosed
WO-2020252222-A1 PROGRANULIN MODULATORS AND METHODS OF USING THE SAME ARKUDA THERAPEUTICS (US) 2020-12-17 WO disclosed
WO-2020252222-A1 PROGRANULIN MODULATORS AND METHODS OF USING THE SAME ARKUDA THERAPEUTICS (US) 2020-12-17 WO disclosed
EP-3724188-A1 PROGRANULIN MODULATORS AND METHODS OF USING THE SAME Arkuda Therapeutics (US) 2020-10-21 EP disclosed
WO-2019118528-A1 PROGRANULIN MODULATORS AND METHODS OF USING THE SAME ARKUDA THERAPEUTICS (US) 2019-06-20 WO disclosed
WO-2019118528-A1 PROGRANULIN MODULATORS AND METHODS OF USING THE SAME ARKUDA THERAPEUTICS (US) 2019-06-20 WO disclosed
US-7964292-B2 Metal complex, light-emitting device, and display apparatus CANON KABUSHIKI KAISHA (JP) 2011-06-21 US disclosed
US-7964292-B2 Metal complex, light-emitting device, and display apparatus CANON KABUSHIKI KAISHA (JP) 2011-06-21 US disclosed
US-20070228940-A1 METAL COMPLEX, LIGHT-EMITTING DEVICE, AND DISPLAY APPARATUS CANON KABUSHIKI KAISHA (JP) 2007-10-04 US disclosed
US-20070228940-A1 METAL COMPLEX, LIGHT-EMITTING DEVICE, AND DISPLAY APPARATUS CANON KABUSHIKI KAISHA (JP) 2007-10-04 US disclosed
US-4321382-A 2-Amino-11b-aryl-benzo[a]quinolizines RICHARDSON-MERRELL INC. (US) 1982-03-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220251084-A1 PROGRANULIN MODULATORS AND METHODS OF USING THE SAME GRN, PRNP, PSEN2 MAPK10 2055/4885NOS3 4353/4885NOS2 4393/4885
US-20070228940-A1 METAL COMPLEX, LIGHT-EMITTING DEVICE, AND DISPLAY APPARATUS LAGE3, EMC2, INTS9 MAPK10 2123/4885NOS3 2064/4885NOS2 1223/4885
US-20220409593-A1 PROGRANULIN MODULATORS AND METHODS OF USING THE SAME GRN, PSEN1, PSEN2 MAPK10 1664/4885NOS3 4047/4885NOS2 3871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.